Medtronic PLC $MDT Stock: Willis Investment Counsel Raises Holdings

20 Oct 2026, 13:29 by Teresa Graham · The Cerbat Gem

Willis Investment Counsel grew its position in Medtronic PLC (NYSE:MDT – Free Report) by 2.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 423,859 shares of the medical technology company’s stock after acquiring an additional 9,320 shares during the period. Medtronic comprises approximately 1.6% of Willis Investment Counsel’s investment portfolio, making the stock its 15th biggest position. Willis Investment Counsel’s holdings in Medtronic were worth $36,575,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of MDT. WCM Investment Management LLC purchased a new position in shares of Medtronic in the 1st quarter valued at about $965,922,000. First Eagle Investment Management LLC raised its holdings in Medtronic by 37.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares during the period. Cullen Capital Management LLC acquired a new position in Medtronic in the 2nd quarter worth about $202,764,000. State Street Corp boosted its position in Medtronic by 2.7% during the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares in the last quarter. Finally, Amundi boosted its position in Medtronic by 36.3% during the first quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after purchasing an additional 1,616,739 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: CE Mark expands pacemaker opportunity: Medtronic received European CE Mark approval for its Vitalis family of next-generation conduction-system pacemakers. The products are designed to support more physiologic pacing and could strengthen Medtronic’s position in the cardiac rhythm management market. Medtronic nets CE Mark for Vitalis family of conduction system pacemakers
Positive Sentiment: Leadership and portfolio repositioning: Medtronic appointed Michael Marinaro as president with an expanded role and completed the separation of its MiniMed diabetes business following an oversubscribed exchange. The changes may allow management to focus more closely on higher-priority medical-device markets, although execution will remain important. Medtronic appoints new president and completes MiniMed spinoff
Neutral Sentiment: Cardiac-monitoring market backdrop: A new industry forecast highlights growth in U.S. wireless cardiac monitoring through expanded reimbursement, telehealth adoption and AI-enabled wearables. The trend is favorable for Medtronic’s broader cardiac-care franchise, but the report does not represent company-specific revenue guidance. U.S. Wireless Cardiac Monitoring Systems Market forecast
Negative Sentiment: ETF outflows and insider selling create pressure: One report estimated $94.9 million of net ETF selling in Medtronic on October 16. Separately, company executives disclosed stock sales, including a CEO transaction valued at approximately $4.75 million and another preplanned sale of 10,420 shares. Because some transactions were scheduled in advance, they may reflect portfolio planning rather than a negative view of the business, but they can weigh on sentiment. Medtronic sees net ETF selling

Analyst Upgrades and Downgrades

Several analysts have commented on MDT shares. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Wednesday, October 14th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. Evercore set a $105.00 target price on Medtronic in a research note on Monday, July 6th. Bank of America increased their target price on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Finally, Weiss Ratings raised shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Eighteen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.

Get Our Latest Research Report on Medtronic

Medtronic Price Performance

Medtronic stock traded up $1.69 during midday trading on Tuesday, reaching $94.46. The company had a trading volume of 1,369,843 shares, compared to its average volume of 11,428,069. The company has a market capitalization of $120.83 billion, a P/E ratio of 23.27, a P/E/G ratio of 2.16 and a beta of 0.55. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The firm’s fifty day simple moving average is $91.10 and its 200-day simple moving average is $85.05. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. During the same period in the previous year, the firm posted $1.26 EPS. Medtronic’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were paid a $0.72 dividend. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.0%. Medtronic’s payout ratio is currently 70.94%.

Insider Transactions at Medtronic

In related news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,903 shares of company stock valued at $5,889,203 over the last ninety days. Insiders own 0.27% of the company’s stock.

About Medtronic

(Free Report)

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.